Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/14/2009 First Published: 8/13/2006


1.		Phase III Randomized Study of Zoledronate, Vitamin D, and Calcium With or Without Strontium Chloride Sr 89 or Samarium Sm 153 Lexidronam Pentasodium in Preventing or Delaying Skeletal-Related Events in Patients With Bone Metastases Secondary to Prostate, Lung, or Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				NCI				RTOG-0517 RTOG 0517, NCT00365105


2.		Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Pharmaceutical / Industry				424Sm32 NCT00121095


3.		Effect of Samarium on the Relief of Pain Due to Vertebral Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Active				18 to 80				Other				NYM-354 NCT00374751

Last Modified: 9/25/2008 First Published: 3/16/2007


4.		Phase II Randomized Pilot Study of Samarium Sm 153 Lexidronam Pentasodium With Versus Without Recombinant Fowlpox-TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, and Sargramostim (GM-CSF) in Patients With Androgen-Insensitive, Prostate Cancer Metastatic to the Bone

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-07-C-0106 07-C-0106, 7678, NCT00450619


5.		Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Behavioral study, Treatment				Active				18 to 65				Other				2006-0349 NCT00429507

Last Modified: 12/9/2008 First Published: 10/26/2007


6.		Phase II Study of Samarium Sm 153 Lexidronam Pentasodium Followed by Intensity-Modulated Radiation Therapy or Three-Dimensional Conformal Radiation Therapy in Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				RTOG-0622 RTOG 0622, NCT00551525


7.		Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				02C.172 NCT00328614

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute